WHITENEST PHARMA ANNOUNCES STRATEGIC CDMO PARTNERSHIP TO ACCELERATE LYSADERM DEVELOPMENT
WhiteNest Pharma is excited to announce a pivotal partnership with a leading Contract Development and Manufacturing Organisation (CDMO) that specializes in pharmaceutical Good Manufacturing Practices (GMP) conditions and holds the Manufacturing Importation Authorisation (MIA) for our product category. This strategic… Leggi tutto »WHITENEST PHARMA ANNOUNCES STRATEGIC CDMO PARTNERSHIP TO ACCELERATE LYSADERM DEVELOPMENT